Outcome of Parkinson's Disease Patients Affected by COVID‐19
Open accessThe DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
There is extensive debate on the neurological consequences of corona virus disease 2019 (COVID-19) and the impact this might have for patients with neurodegenerative conditions, including Parkinson's disease (PD). Older advanced PD patients may represent a particularly vulnerable population, as respiratory muscle rigidity as well as impairment of cough reflex alongside preexisting dyspnoea may lead to increased severity of COVID-19.1 In addition, there are indirect possible effects, such as the impact of stress, self-isolation, and anxiety, as well as the consequences of prolonged immobility because of the lockdown.2, 3 Several observations make the link between COVID-19 and PD particularly intriguing. Antibodies against coronavirus were found in the cerebrospinal fluid of PD patients more than 2 decades ago, suggesting a possible role for viral infections in neurodegeneration.4 Angiotensin-converting enzyme 2 (ACE2) receptors are highly expressed in dopamine neurons, and they are reduced in PD because of the degenerative process; therefore, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)–related brain penetration may cause additional harm and worsen symptoms and may increase the requirement of dopamine replacement therapy, as evident in 5 of our cases.5, 6 Interestingly, the ability of coronaviruses to enter the brain through the nasal cavity determines anosmia/hyposmia and ageusia in many infected subjects, a symptomatology that closely resembles one of the most prominent premotor symptom of PD.7 Finally, the dopamine synthetic pathway is possibly involved in the pathophysiology of COVID-19, as ACE2 and dopamine decarboxylase coexpress and coregulate in nonneuronal cell types, which may indicate dopamine depletion and the need for considering levodopa as treatment.8 Outcomes of PD patients infected by SARS-CoV-2 are unknown. We present here the outcome of 10 clinical cases (Table 1) collected from the experience at the Parkinson and Movement Disorders Unit in Padua, Italy, and the Parkinson's Foundation Centre of Excellence at King's College Hospital in London, UK, from the beginning of March to the current period. The PD center in Padua has a catchment of 1022 patients, mainly in the province of Padua, which had 3407 cases of COVID-19, 2 of whom were advanced PD patients. Both were women residing in nursing homes with severe motor manifestations, and both were treated with levodopa therapy (Table 1). One remained asymptomatic, whereas the other, who in the last months had been suffering from deteriorating cognition and hallucinations, developed respiratory problems and died. The King's center has 4000 PD patients in the catchment and is currently following more than 600 patients. In all, thus far, 8 cases have been identified with COVID-19, and clinical details are presented here. The Kings' COVID-19 PD group consists of 6 men and 2 women, all older than 60 years of age with severe motor dysfunction, comorbidities, and most requiring additional levodopa dosing following infection (Table 1). Anxiety and other nonmotor features, such as fatigue, orthostatic hypotension, cognitive impairment, and psychosis, also worsened during the infection. Fatigue was a dominant symptom during the SARS-CoV-2 infection in all cases on advanced therapies. Three patients died from COVID-19 pneumonia. Rotigotine 4 mg 1 patch once daily Safinamide 50 mg 1 tablet once daily These findings suggest that PD patients of older age (mean, 78.3 years) with longer disease duration (mean, 12.7 years) are particularly susceptible to COVID-19 with a substantially high mortality rate (40%). Those on advanced therapies, such as deep brain stimulation or levodopa infusion therapy, seem especially vulnerable, and a mortality rate of 50% among our 4 such cases is of concern. Although 2 recent articles have addressed the issue of COVID-19 in PD, none specifically showed cases directly affected by COVID-19, and we believe ours is the first report of this nature.2, 3 The report of Prasad et al focuses on the perceptions of SARS-CoV-2 infection in 100 PD patients and some symptoms listed tally with our observations in a real-life population with COVID-19.2 Many national and charity guidelines do not list PD or specifically older subjects on advanced therapies as a susceptible group, and this information needs to be amended in light of these new data.9 The views expressed are those of the authors and not necessarily those of the NHS, NIHR, or Department of Health. There are no funding sources to disclose. The authors also thank all clinicians and front-line staff engaged in the care of COVID-19 patients at King's College and Princess Royal Hospitals, London, UK, as well as at the Parkinson and Movement Disorders Unit in Padua, Italy. Angelo Antonini: conception, data collection, manuscript, review and critique. Valentina Leta: data collection, review and critique. James Teo: data collection, review and critique. K Ray Chaudhuri: conce
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Helmich, R. C., & Bloem, B. R. (2020) · Journal of Parkinson's Disease · doi:10.3233/jpd-202038 · Cited by 300
Cited by
Bloem, B. R., Okun, M. S., & Klein, C. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00218-x · Cited by 3,920
The neuropsychiatry of Parkinson's disease: advances and challenges
Weintraub, D., Aarsland, D., Chaudhuri, K. R., Dobkin, R. D., Leentjens, A. F., Rodriguez-Violante, M., & Schrag, A. (2022) · The Lancet Neurology · doi:10.1016/s1474-4422(21)00330-6 · Cited by 450
Self-citationEffects of COVID‐19 on Parkinson's Disease Clinical Features: A Community‐Based Case‐Control Study
Cilia, R., Bonvegna, S., Straccia, G., Andreasi, N. G., Elia, A. E., Romito, L. M., Devigili, G., Cereda, E., & Eleopra, R. (2020) · Movement Disorders · doi:10.1002/mds.28170 · Cited by 185
The Effect of the COVID-19 Pandemic on People with Parkinson’s Disease
Brown, E. G., Chahine, L. M., Goldman, S. M., Korell, M., Mann, E., Kinel, D. R., Arnedo, V., Marek, K. L., & Tanner, C. M. (2020) · Journal of Parkinson's Disease · doi:10.3233/jpd-202249 · Cited by 177
van der Heide, A., Meinders, M. J., Bloem, B. R., & Helmich, R. C. (2020) · Journal of Parkinson’s Disease · doi:10.3233/jpd-202251 · Cited by 126
Metadata
- Authors
- Antonini, A., Leta, V., Teo, J., & Chaudhuri, K. R.
- Venue
- Movement Disorders
- Publisher
- Wiley
- Published
- 2020-05-28
- Volume
- 35
- Issue
- 6
- Pages
- 905-908
- ISSN
- 0885-3185 (ISSN-L)
- 1531-8257
- OpenAlex
- W3019518954
- Cited by
- 232
- References
- 1
- FWCI
- 18.83
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.